Global Bradykinin Receptor Antagonists Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Bradykinin Receptor Antagonists market size was valued at US$ 155 million in 2025 and is forecast to a readjusted size of US$ 265 million by 2032 with a CAGR of 7.9% during review period.
Bradykinin receptor antagonists are a class of therapeutics designed to block bradykinin signaling by preventing bradykinin from binding to its receptors—most notably the B2 receptor (with the B1 receptor implicated in certain inducible inflammatory settings). By interrupting this pathway, these agents reduce bradykinin-driven vasodilation, increased vascular permeability, and amplification of pain and inflammatory signaling. Clinically, their key value lies in addressing conditions where excessive bradykinin activity is the primary driver of symptoms, such as acute attacks of hereditary angioedema (HAE) characterized by subcutaneous or mucosal swelling, and other bradykinin-mediated permeability or inflammatory pain states. Unlike purely symptomatic approaches (e.g., antihistamines or corticosteroids) that are often ineffective in non–histamine-mediated angioedema, bradykinin receptor antagonists target the underlying mechanism, offering a mechanism-based option when the kallikrein–kinin system is dysregulated. Historically, this product category emerged from decades of research into the kallikrein–kinin cascade and B1/B2 receptor pharmacology, progressing from early research tool compounds and peptide-based leads to clinically usable receptor-blocking molecules and practical dosing regimens, with ongoing refinement focused on rapid onset, attack control, convenience, and safety. Upstream, the supply chain typically includes active pharmaceutical ingredient (API) manufacturing and key intermediates (fine chemical feedstocks, amino-acid/peptide or small-molecule building blocks, chiral reagents, catalysts, solvents), formulation excipients (buffers, stabilizers, surfactants, preservatives), and sterile drug-product components and consumables (vials and stoppers, prefilled syringe assemblies, needles and safety devices, sterile filters, single-use tubing sets, aseptic filling and packaging materials), supported by chemical and intermediate suppliers, CDMO/CMO partners, and packaging/device component manufacturers.In 2025, the global production capacity of bradykinin receptor antagonists is estimated at 400,000 doses, with sales reaching 313,000 doses. The average selling price is approximately USD 481.5 per dose, and the gross margin of manufacturers generally ranges between 60% and 70%.
In the current landscape, bradykinin receptor antagonists have secured a defined niche within clinical practice and drug development, especially for conditions where bradykinin-mediated pathophysiology plays a central role, such as hereditary angioedema and acute permeability-driven symptoms. Their strong mechanistic focus and rapid symptomatic response have elevated their status from niche experimental treatments to recognized therapy options in specific clinical scenarios. As molecularly targeted drug development techniques have matured, an increasing number of pharmaceutical companies and research institutions have adopted bradykinin pathway modulation as a strategic intervention point for inflammation and vascular permeability anomalies, broadening clinical familiarity and acceptance. Growing real-world evidence and clinical experience have further solidified clinician confidence in identifying and managing bradykinin-driven conditions, contributing to wider therapeutic adoption among specialists.
Looking forward, the development trajectory for bradykinin receptor antagonists is expected to emphasize enhanced efficacy, improved convenience, and broader therapeutic applicability. Continued advances in molecular design and pharmacokinetic optimization are anticipated to yield next-generation receptor antagonists with faster onset, tailored half-lives, better safety profiles, and more patient-friendly administration. Efforts to expand indications are already underway, exploring bradykinin pathway modulation in inflammatory pain, chronic vascular permeability disorders, and perioperative complication management—areas with unmet clinical needs. Furthermore, the increasing integration of precision medicine principles could facilitate individualized treatment approaches, leveraging patient-specific pathological characteristics and biomarkers to refine therapeutic decisions and improve outcome predictability. Cross-disciplinary integration in discovery platforms, combining computational pharmacology, high-throughput screening, and iterative clinical feedback, is likely to accelerate the translation of novel concepts into practice.
On the drivers and barriers front, the field benefits from deepening biological insights into the bradykinin system, the maturity of targeted drug development platforms, and a growing clinical demand for mechanism-based interventions, all of which sustain momentum for research and market growth. Regulatory and policy support, particularly for therapies addressing rare diseases, further bolsters development prospects. However, significant challenges remain, including the inherent complexity of the bradykinin pathway in both physiological and pathological contexts, which raises safety and specificity considerations for targeted interventions. Patient heterogeneity in certain indications complicates efficacy evaluation and clinical trial design. Moreover, the molecular characteristics and delivery requirements of receptor antagonists present cost and manufacturing challenges, erecting technical barriers especially for smaller developers. Finally, expanding indications often necessitates robust clinical evidence, and generating such data across diverse pathophysiological contexts demands considerable time and resources, potentially slowing the translation of promising applications into clinical reality.
This report is a detailed and comprehensive analysis for global Bradykinin Receptor Antagonists market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Bradykinin Receptor Antagonists market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Bradykinin Receptor Antagonists market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Bradykinin Receptor Antagonists market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Bradykinin Receptor Antagonists market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Bradykinin Receptor Antagonists
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Bradykinin Receptor Antagonists market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Takeda Pharmaceuticals, Eugia Pharma Specialities, Glenmark Pharmaceuticals, Sandoz, Cipla, Fresenius Kabi, Jiangsu Hengrui Pharmaceuticals, Chengdu Shengnuo Biology Pharmacy, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Bradykinin Receptor Antagonists market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Icatibant
Fasitibant
Others
Market segment by Molecular Modality
Peptide-Based Antagonists
Non-Peptide Small-Molecule Antagonists
Biologic-Based Antagonists
Peptidomimetics
Market segment by Route Of Administration
Subcutaneous Injection
Intravenous Injection
Oral Administration
Market segment by Application
Hospital and Clinic
Pharmacy
Other
Major players covered
Takeda Pharmaceuticals
Eugia Pharma Specialities
Glenmark Pharmaceuticals
Sandoz
Cipla
Fresenius Kabi
Jiangsu Hengrui Pharmaceuticals
Chengdu Shengnuo Biology Pharmacy
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Bradykinin Receptor Antagonists product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Bradykinin Receptor Antagonists, with price, sales quantity, revenue, and global market share of Bradykinin Receptor Antagonists from 2021 to 2026.
Chapter 3, the Bradykinin Receptor Antagonists competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bradykinin Receptor Antagonists breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Bradykinin Receptor Antagonists market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Bradykinin Receptor Antagonists.
Chapter 14 and 15, to describe Bradykinin Receptor Antagonists sales channel, distributors, customers, research findings and conclusion.